New targets at ASH hint at an emerging T cell cancer focus

Target innovation for hematological malignancies could be shifting from B cell lymphomas to T cell cancers, according to an analysis by BioCentury of new drug targets being presented at ASH21. 

The analysis identifies 22 new targets in abstracts released ahead of the American Society of Hematology (ASH) annual meeting, with a new target defined as one that hasn’t been addressed by any disclosed preclinical, clinical or approved product listed in BioCentury’s BCIQ database. ...